J Oncol Pharm Pract 11:13–19CrossRef Den Brok MW, Nuijen B, Hillebrand MJ, Grieshaber CK, Harvey MD, Beijnen JH (2005b) Development and validation of an LC-UV method for the quantification and purity PXD101 chemical structure determination of the novel anticancer agent C1311 and its pharmaceutical dosage form. J Pharm Biomed Anal 39:46–53CrossRef Den Brok MW, Nuijen B, Kettenes-Van Den Bosch

JJ, Van Steenbergen MJ, Buluran JN, Harvey MD, Grieshaber CK, Beijnen JH (2005c) Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311. PDA J Pharm Sci Technol 59:285–297 Dziegielewski J, Konopa J (1996) Interstrand crosslinking of DNA induced in tumor cells by a new group of antitumor imidazoacridinones. Proc Am Assoc Cancer Res 37:410 Dziegielewski J, Slusarski

B, Konitz A, Skladanowski A, Konopa J (2002) Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity. Biochem Pharmacol 63:1653–1662PubMedCrossRef Hyzy M, Bozko P, Konopa J, Skladanowski A (2005) Antitumour imidazoacridone C-1311 induces cell death by mitotic catastrophe in human colon selleck inhibitor carcinoma cells. Biochem Pharmacol 69:801–809PubMedCrossRef Ivanciuc O (1996) HyperChem release 4.5 for Windows. Inf Comput Sci 36:612–614CrossRef Kaliszan R, Turowski M, Buciński A, Hartwick RA (1995) Quantitative structure-retention relationships in capillary electrophoresis of inorganic cations and β-adrenolytic and sulfonamided compomids. Quant Struct

Act Relat 14:356–361CrossRef Koba M, Konopa J (2007) Interactions of antitumor triazoloacridinones with DNA. Acta Biochim Pol 54:297–306PubMed Koba M, Koba K, Bączek T (2009) Is Vorinostat DNA minor groove binding crucial for biological activity of triazoloacridinones with cytotoxic and antitumour properties? Lett Drug Des Discov 6:242–245CrossRef Kusnierczyk H, Cholody WM, Paradziej-Łukowicz J, Radzikowski C, Konopa J (1994) Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones. Arch Immunol Ther Exp 42:414–423 Lamb J, Wheatley DN (1996) Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation. Br J Cancer 74:1359–1368PubMedCrossRef Lemke K, Poindessous V, Składanowski A, Larsen AK (2004) The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties. Mol Pharmacol 66:1035–1042PubMedCrossRef Lemke K, Wojciechowski M, Laine W, Bailly C, Colson P, Baginski M, Larsen AK, Skladanowski A (2005) Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities. Nucleic Acids Res 33:6034–6047PubMedCrossRef Mazerska Z, Augustin E, Dziegielewski J, Chołody MW, Konopa J (1996) QSAR of acridines, III. Structure-activity relationship for antitumour imidazoacridinones and find more intercorrelations between in vivo and in vitro tests.